Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome

Curr Opin Pulm Med. 2014 Jul;20(4):340-6. doi: 10.1097/MCP.0000000000000060.

Abstract

Purpose of review: Pulmonary manifestations have been well described in leukemia, but pleural disease is less common. This review highlights pleural effusions in acute and chronic leukemia and myelodysplastic syndrome (MDS) based on the evidence to date. Diagnostic workup and recommendations for the management of these effusions are also outlined.

Recent findings: Pleural effusions in patients with leukemia are most often due to infection and to a lesser extent leukemic infiltration of the pleura. The prognostic implications of these effusions are unclear, but survival is most likely determined by the underlying malignancy and its response to treatment. New therapies have changed survival in these patients, and some of these treatments, such as tyrosine kinase inhibitors, have emerged as important causes for these effusions. Pleural interventions may be accomplished with few complications.

Summary: Pleural effusions may occur with acute and chronic leukemia and MDS. Infection remains the most common cause. Malignant pleural effusions tend to occur in advanced disease in chronic leukemia, but they can be seen at any time with acute leukemia and MDS. With standard precautions, pleural procedures may be performed safely in this population. In cases of unclear cause, pleural and bone marrow biopsy should be considered.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Biopsy
  • Bone Marrow / pathology
  • Chronic Disease
  • Dasatinib
  • Humans
  • Leukemia / complications
  • Leukemia / pathology*
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / pathology*
  • Pleura / pathology
  • Pleural Effusion / chemically induced
  • Pleural Effusion / etiology*
  • Pleural Effusion / pathology*
  • Prognosis
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / adverse effects
  • Thiazoles / adverse effects

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Dasatinib